MSS/ MMRp
我们是谁
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
抗程序性死亡配体-1 Durvalumab抗体（MEDI4736）与奥拉帕利（Olaparib）和/或塞地拉尼（Cediranib）联合治疗晚期实体瘤和晚期或复发性卵巢癌、三阴性乳腺癌、肺癌、前列腺癌和结直肠癌的I/II期研究...
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
Pembrolizumab 在 MMR 精通的转移性结直肠癌中的药理作用触发高突变状态
Pembrolizumab In Central Nervous System Metastases
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
对间皮素阳性多发性实体瘤患者进行的 CRISPR-Cas9 介导的 PD-1 和 TCR 基因敲除间皮素定向 CAR-T 细胞研究。
重组白细胞介素-15 与检查点抑制剂 Nivolumab 和 Ipilimumab 联合治疗难治性癌症患者
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
